GO:0007212 G protein-coupled dopamine receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007212 describes the biological process that begins when dopamine binds a G protein-coupled dopamine receptor on the cell surface and ends with regulation of a downstream cellular response.
• Five dopamine receptor subtypes (D1-D5) are encoded by DRD1, DRD2, DRD3, DRD4 and DRD5; D1-like receptors (D1, D5) couple to Gs/olf and D2-like receptors (D2, D3, D4) couple to Gi/o.
• Receptor desensitization and trafficking are controlled by G protein-coupled receptor kinases (GRK2, GRK3, GRK5, GRK6) and arrestins, which shape the duration and location of dopamine signals.
• Dopamine signaling is spatially and temporally discrete in the striatum, with distinct release and clearance kinetics that determine which receptors are engaged.
• Dysregulated dopamine receptor signaling is implicated in Parkinson disease, schizophrenia, addiction, hypertension and metabolic or fibrotic disorders such as non-alcoholic steatohepatitis.
• CRISPR knockout, point-mutation, knock-in and overexpression cell models, combined with CRISPR library screening and bioinformatics, allow causal dissection of dopamine receptor pathway genes.
Description
The Gene Ontology biological process GO:0007212, G protein-coupled dopamine receptor signaling pathway, defines the sequence of molecular events that starts when dopamine binds to a dopamine receptor on the surface of a target cell and concludes with regulation of a downstream cellular process. Dopamine is a catecholamine neurotransmitter that controls motor activity, motivation, reward, cognition and neuroendocrine function, and its actions are mediated by five G protein-coupled receptor subtypes, D1 through D5. Because these receptors are expressed in the central nervous system and in peripheral tissues, the pathway is a central node in neurobiology, cardiovascular physiology and immunometabolism. At the molecular level, dopamine receptors are seven-transmembrane receptors that activate heterotrimeric G proteins: D1-like receptors (D1 and D5) couple to Gs/olf to stimulate adenylyl cyclase and cyclic AMP production, whereas D2-like receptors (D2, D3 and D4) couple to Gi/o to inhibit cyclic AMP production and modulate ion channels and other effectors. The pathway is not a simple on-off switch; it is tuned by receptor phosphorylation, arrestin recruitment, internalization and degradation, processes largely governed by G protein-coupled receptor kinases. For researchers, GO:0007212 provides a standardized framework for interpreting transcriptomic, proteomic and functional screens that perturb dopamine signaling. It links receptor-level events to downstream cellular outcomes and to disease phenotypes such as Parkinson disease, schizophrenia, addiction, hypertension and non-alcoholic steatohepatitis, making it a high-value target for CRISPR-based causal studies.
G protein-coupled dopamine receptor signaling pathway At A Glance
| GO ID | GO:0007212 |
|---|---|
| GO term | G protein-coupled dopamine receptor signaling pathway |
| Ontology | biological_process |
| Synonym | dopamine receptor signalling pathway |
| Definition | A G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. |
| Major function | Transduces extracellular dopamine signals into intracellular responses through Gs/olf- or Gi/o-coupled receptors. |
| Receptor subtypes | D1-like (D1, D5) and D2-like (D2, D3, D4) dopamine receptors. |
| Key regulators | G protein-coupled receptor kinases and arrestins control desensitization and trafficking. |
| Disease relevance | Parkinson disease, schizophrenia, addiction, hypertension and non-alcoholic steatohepatitis. |
What Is GO:0007212?
In plain terms, GO:0007212 is the cellular process in which dopamine acts as a first messenger: it binds a G protein-coupled dopamine receptor on the cell surface, the receptor changes shape and activates an intracellular G protein, and the resulting signals alter the activity of downstream effectors and cellular processes. The term covers signaling initiated by dopamine at any of the five dopamine receptor subtypes and ends with regulation of a downstream cellular process, such as changes in cyclic AMP levels, ion channel activity, gene expression or neuronal excitability.
Why Is G protein-coupled dopamine receptor signaling pathway Important in Cell Biology?
GO:0007212 is important because dopamine receptor signaling is one of the most widely studied G protein-coupled receptor pathways in human physiology and disease. It controls motor function, reward, cognition and neuroendocrine output in the brain, and it also regulates peripheral processes such as blood pressure, immune cell behavior and fibrotic remodeling. Because the pathway is initiated by a defined ligand-receptor interaction and is modulated by well-characterized kinases and arrestins, it is experimentally tractable and serves as a model for understanding G protein-coupled receptor biology more broadly.
• Provides a mechanistic framework for dopamine action in motor control, reward, motivation and cognition.
• Explains how D1-like and D2-like receptors produce opposing effects on cyclic AMP and neuronal excitability.
• Links receptor desensitization and trafficking by GRKs and arrestins to the duration and strength of dopamine signals.
• Underlies the pharmacology of antipsychotics, anti-Parkinson drugs and drugs of abuse that target dopamine receptors.
• Is implicated in Parkinson disease and other neurological disorders characterized by dopaminergic dysfunction.
• Contributes to hypertension through G protein-coupled receptor kinase regulation of cardiovascular signaling.
• Modulates profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis, showing peripheral roles.
• Provides a template for studying spatiotemporal encoding of neurotransmitter release in the striatum.
• Offers a rich set of druggable nodes, including receptor subtypes, GRKs and downstream effectors.
• Supports CRISPR-based causal genomics of receptor subtypes and regulators in disease models.
What Happens During G protein-coupled dopamine receptor signaling pathway?
Dopamine binding and receptor activation
In simple terms: Dopamine docks onto its receptor like a key in a lock, switching the receptor on.
The pathway begins when dopamine binds the orthosteric site of a dopamine receptor on the target cell surface. Dopamine receptors are seven-transmembrane G protein-coupled receptors, and ligand binding stabilizes an active receptor conformation that can engage heterotrimeric G proteins. The five subtypes differ in their affinity for dopamine and in their expression patterns, which shapes which cells and circuits respond.
G protein coupling and second messenger regulation
In simple terms: The activated receptor flips a molecular switch inside the cell, changing the level of a small messenger molecule.
D1-like receptors (D1 and D5) couple to Gs/olf and stimulate adenylyl cyclase, raising cyclic AMP and activating protein kinase A, whereas D2-like receptors (D2, D3 and D4) couple to Gi/o and inhibit adenylyl cyclase, lowering cyclic AMP. These opposing actions on second messengers allow dopamine to either excite or inhibit target neurons depending on the receptor subtype expressed.
Downstream effector and cellular responses
In simple terms: The messenger molecule then changes how the cell behaves, for example by altering ion channels or gene expression.
Changes in cyclic AMP and G protein beta-gamma subunits modulate ion channels, kinases and transcription factors, leading to altered neuronal excitability, synaptic plasticity and gene expression. In the striatum, dopamine transmission is encoded with discrete spatiotemporal dynamics that determine which downstream responses are engaged. The pathway ends with regulation of these downstream cellular processes, consistent with the GO:0007212 definition.
Desensitization, internalization and recycling
In simple terms: After signaling, the receptor is temporarily switched off and pulled inside the cell so the response does not run away.
G protein-coupled receptor kinases phosphorylate activated dopamine receptors, promoting arrestin binding, desensitization and internalization. This regulatory arm controls the intensity and duration of dopamine signaling and is important for adapting to sustained or repeated stimulation. GRK-mediated regulation of dopamine receptors also has implications for psychoactive drug effects and for cardiovascular physiology.
Key Genes Involved in GO:0007212 G protein-coupled dopamine receptor signaling pathway
The following genes encode the receptors, G proteins, kinases and effectors that carry out or regulate GO:0007212.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DRD1 | D1-like receptor coupling to Gs/olf and cyclic AMP stimulation | Target for motor and reward studies; knockout and point-mutation models |
| DRD2 | D2-like receptor coupling to Gi/o and cyclic AMP inhibition | Central to antipsychotic and anti-Parkinson pharmacology; knockout models |
| DRD3 | D2-like receptor modulating limbic circuits | Implicated in motivation and addiction research |
| DRD4 | D2-like receptor with enriched cortical expression | Studied in cognition and attention phenotypes |
| DRD5 | D1-like receptor stimulating cyclic AMP | Studied in hippocampal and peripheral signaling |
| GNAS | Encodes Gs alpha subunit for D1-like signaling | Required for cyclic AMP responses; knockout and knock-in models |
| GNAO1 | Encodes Go alpha subunit enriched in neurons | Links D2-like receptors to neuronal effectors |
| GNB1 | G protein beta subunit in heterotrimers | Modulates effector coupling and signaling specificity |
| GNG2 | G protein gamma subunit in heterotrimers | Contributes to receptor-G protein coupling |
| GRK2 | Phosphorylates activated dopamine receptors | Regulates desensitization; knockout and kinase-dead models |
| GRK3 | G protein-coupled receptor kinase in dopamine pathways | Modulates receptor responsiveness |
| GRK5 | G protein-coupled receptor kinase with cardiovascular roles | Linked to hypertension and receptor regulation |
| GRK6 | G protein-coupled receptor kinase regulating D2-like receptors | Studied in striatal signaling and drug responses |
| ARRB1 | Beta-arrestin 1 mediating receptor internalization | Controls trafficking and biased signaling |
| ARRB2 | Beta-arrestin 2 mediating receptor desensitization | Key node for signaling bias studies |
| ADCY5 | Adenylyl cyclase producing cyclic AMP | Effector of D1-like signaling; knockout models |
| PPP1R1B | DARPP-32 integrating dopamine and glutamate signals | Readout of striatal dopamine signaling |
How Is G protein-coupled dopamine receptor signaling pathway Regulated?
GO:0007212 is regulated at multiple levels. Receptor availability and sensitivity are controlled by G protein-coupled receptor kinases, which phosphorylate activated receptors and promote arrestin-mediated desensitization and internalization. GRK2, GRK3, GRK5 and GRK6 have distinct expression patterns and substrate preferences, allowing cell-type-specific tuning of dopamine responses. In the cardiovascular system, GRK regulation of G protein-coupled receptors contributes to hypertension pathophysiology and is considered a therapeutic target. Spatiotemporal regulation of dopamine release and clearance in the striatum further shapes which receptors are activated and for how long. Finally, receptor subtype expression and G protein availability determine whether dopamine produces excitatory or inhibitory downstream effects.
G protein-coupled dopamine receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DRD2 | Schizophrenia, addiction and non-alcoholic steatohepatitis | Knockout and point-mutation cell models; macrophage-endothelial co-culture |
| DRD1 | Motor dysfunction and reward disorders | Knockout and overexpression neuronal cell lines |
| GRK2 | Hypertension and cardiovascular remodeling | Kinase-dead knock-in and knockout models |
| GRK6 | Striatal signaling and drug responses | Knockout and tagged knock-in models |
| ARRB2 | Biased signaling and receptor trafficking | Knockout and fluorescent knock-in models |
Neurodegeneration and Parkinson disease
Dopamine receptor signaling is central to motor control, and loss of dopaminergic neurons in Parkinson disease disrupts GO:0007212-dependent circuits, contributing to bradykinesia, rigidity and tremor. Dopamine replacement therapy and receptor-targeting drugs act directly on this pathway.
Schizophrenia and addiction
Altered dopamine receptor signaling, particularly through D2-like receptors, is implicated in schizophrenia and in reward-related disorders including addiction. Psychoactive drugs modulate striatal dopamine transmission, and GRK-mediated regulation influences drug responses.
Hypertension and cardiovascular regulation
G protein-coupled receptor kinases that regulate dopamine receptors also participate in blood pressure control, and GRK dysfunction is linked to hypertension pathogenesis. This connects GO:0007212 to cardiovascular therapeutic development.
Metabolic and fibrotic disease
Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis, demonstrating that GO:0007212 operates in peripheral immune-metabolic contexts beyond the brain.
From G protein-coupled dopamine receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is DRD2 required for a downstream cellular response? | DRD2 knockout cell line |
| Does a disease-associated DRD1 variant alter cyclic AMP signaling? | DRD1 point-mutation knock-in cell line |
| Where and when is DRD2 expressed and trafficked? | Tagged DRD2 knock-in with fluorescent tag |
| Does GRK6 overexpression change receptor desensitization? | GRK6 overexpression cell line |
| Which genes modify dopamine receptor signaling? | CRISPR library screening in a dopamine-responsive reporter line |
| Does ARRB2 loss alter receptor internalization? | ARRB2 knockout cell line |
How to Study the G protein-coupled dopamine receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA sequencing | Transcriptome changes after pathway perturbation | Identify downstream genes of dopamine receptor signaling |
| Cyclic AMP assay | Second messenger levels | Distinguish D1-like and D2-like receptor activity |
| Western blotting | Protein expression and phosphorylation | Assess GRK-mediated receptor phosphorylation |
| Live-cell imaging | Receptor trafficking and localization | Track internalization and recycling |
| CRISPR knockout screening | Gene requirement for pathway output | Discover modifiers of dopamine signaling |
| Proteomics | Protein interactions and post-translational changes | Map receptor complexes and signaling networks |
| Electrophysiology | Neuronal excitability and synaptic responses | Measure functional consequences of receptor activation |
| Bioinformatics pathway analysis | Enrichment of GO:0007212 and related terms | Interpret omics data in a pathway context |
Transcriptomic and pathway profiling
RNA sequencing of cells or tissues with perturbed dopamine receptor signaling can identify downstream transcriptional programs and confirm pathway engagement. Comparing wild-type and knockout lines reveals genes whose expression depends on GO:0007212 activity.
Second messenger and signaling assays
Cyclic AMP assays, reporter systems and kinase activity measurements directly quantify the second messenger changes that define D1-like versus D2-like receptor signaling. These assays are standard readouts for receptor subtype function.
Receptor trafficking and imaging
Fluorescently tagged receptors and live-cell imaging can track internalization, recycling and subcellular localization after dopamine stimulation. Spatiotemporal imaging in striatal preparations has revealed discrete encoding of dopamine transmission.
Genetic and pharmacological perturbation
Knockout, knockdown and pharmacological blockade of receptors, GRKs or arrestins can establish causal roles for specific pathway components. Such experiments link molecular events to cellular and organismal phenotypes.
How CRISPR Can Be Used to Study GO:0007212 G protein-coupled dopamine receptor signaling pathway
Knockout
CRISPR knockout of DRD1, DRD2, GRK genes or ARRB genes removes the protein and reveals its requirement for dopamine receptor signaling and downstream cellular responses. Knockout cell lines are foundational for assigning causal roles within GO:0007212.
Point Mutation
Point-mutation knock-in can model disease-associated variants or kinase-dead versions of GRKs to test how specific residues affect receptor phosphorylation and desensitization. Such models help distinguish loss-of-function from gain-of-function mechanisms.
Knock-in
Tagged knock-in of dopamine receptors or arrestins enables visualization and purification of endogenous complexes without overexpression artifacts. Knock-in reporters can also place fluorescent or luminescent tags under endogenous regulatory control.
Overexpression
Overexpression of receptors, G proteins or GRKs can amplify pathway output and test sufficiency in cellular models. Overexpression systems are useful for pharmacology and for comparing signaling bias between receptor subtypes.
How EDITGENE Supports G protein-coupled dopamine receptor signaling pathway Research
Researchers studying G protein-coupled dopamine receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, desensitization or downstream cellular responses. EDITGENE provides publication-ready CRISPR cell models and screening services that let teams move from correlation to causation for GO:0007212 genes such as DRD1, DRD2, GRK2, GRK6 and ARRB2.
Contact EDITGENE today to design your custom CRISPR model for G protein-coupled dopamine receptor signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GNAO1 Knockout HEK293 Cell Line | EDJ-KQ750 | Human | 2775 | Details Get a Quote |
| GNB5 Knockout HEK293 Cell Line | EDJ-KQ801 | Human | 10681 | Details Get a Quote |
| DRD2 Knockout HEK293 Cell Line | EDC90437 | Human | 1813 | Details Get a Quote |
| DRD1 Knockout HEK293 Cell Line | EDJ-KQ1554 | Human | 1812 | Details Get a Quote |
| DRD5 Knockout HEK293 Cell Line | EDJ-KQ1555 | Human | 1816 | Details Get a Quote |
| SLC1A1 Knockout HEK293 Cell Line | EDJ-KQ5760 | Human | 6505 | Details Get a Quote |
| RGS9 Knockout HEK293 Cell Line | EDJ-KQ6361 | Human | 8787 | Details Get a Quote |
| SLC1A1 Knockout A-549 Cell Line | EDJ-KQ29174 | Human | 6505 | Details Get a Quote |
| SLC1A1 Knockout HCT 116 Cell Line | EDJ-KQ29175 | Human | 6505 | Details Get a Quote |
| SLC1A1 Knockout HeLa Cell Line | EDJ-KQ29176 | Human | 6505 | Details Get a Quote |
| GNB5 Knockout A-549 Cell Line | EDJ-KQ19531 | Human | 10681 | Details Get a Quote |
| GNB5 Knockout HCT 116 Cell Line | EDJ-KQ19532 | Human | 10681 | Details Get a Quote |
| GNB5 Knockout HeLa Cell Line | EDJ-KQ19533 | Human | 10681 | Details Get a Quote |
| GNAO1 Knockout HeLa Cell Line | EDJ-KQ20751 | Human | 2775 | Details Get a Quote |
| RGS9 Knockout A-549 Cell Line | EDJ-KQ30322 | Human | 8787 | Details Get a Quote |
Displaying Records 1 To 15 Of 30 Records
Frequently Asked Questions About G protein-coupled dopamine receptor signaling pathway
What is GO:0007212?
GO:0007212 is the Gene Ontology biological process for G protein-coupled dopamine receptor signaling pathway, defined as a G protein-coupled receptor signaling pathway initiated by dopamine binding to its receptor on the cell surface and ending with regulation of a downstream cellular process.
What genes are involved in G protein-coupled dopamine receptor signaling pathway?
Key genes include the five dopamine receptor genes DRD1, DRD2, DRD3, DRD4 and DRD5, G protein subunits such as GNAS and GNAO1, and regulators such as GRK2, GRK3, GRK5, GRK6, ARRB1 and ARRB2.
What is the difference between D1-like and D2-like dopamine receptor signaling?
D1-like receptors (D1 and D5) couple to Gs/olf and stimulate cyclic AMP production, while D2-like receptors (D2, D3 and D4) couple to Gi/o and inhibit cyclic AMP production.
How is dopamine receptor signaling desensitized?
G protein-coupled receptor kinases phosphorylate activated dopamine receptors, promoting arrestin binding, desensitization and internalization, which limits the duration of signaling.
Which diseases are linked to dopamine receptor signaling?
Dopamine receptor signaling is linked to Parkinson disease, schizophrenia, addiction, hypertension and non-alcoholic steatohepatitis.
How do researchers study GO:0007212 in the lab?
Common approaches include cyclic AMP assays, RNA sequencing, live-cell imaging of tagged receptors, electrophysiology and CRISPR-based perturbation of receptor and regulator genes.
Can CRISPR knockout be used to study dopamine receptors?
Yes, CRISPR knockout of DRD1, DRD2 or regulator genes such as GRK6 and ARRB2 is widely used to test their requirement for dopamine receptor signaling.
What is the role of GRK6 in dopamine signaling?
GRK6 is a G protein-coupled receptor kinase that regulates dopamine receptor responsiveness and contributes to striatal signaling and drug responses.
Is dopamine receptor signaling only important in the brain?
No, dopamine receptors are also expressed in peripheral tissues, where they influence immune-metabolic processes such as macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
How does dopamine transmission shape signaling in the striatum?
Striatal dopamine transmission is encoded with discrete spatiotemporal dynamics that determine which receptors and downstream pathways are activated.
Conclusion
GO:0007212, G protein-coupled dopamine receptor signaling pathway, is a well-defined biological process that connects dopamine binding at the cell surface to changes in second messengers, ion channels, gene expression and cellular behavior. Its five receptor subtypes, G protein partners, GRKs and arrestins form a tunable system that is central to motor control, reward, cognition, cardiovascular regulation and immune-metabolic function. Because the pathway is genetically tractable, CRISPR knockout, point-mutation, knock-in and overexpression models, together with library screening and bioinformatics, provide a direct route to causal insight into dopamine-related disease mechanisms and therapeutic targets.
References
- 1. Klein MO et al.. 2019. Dopamine: Functions, Signaling, and Association with Neurological Diseases.. Cell Mol Neurobiol 39(1):31-59 PMID: 30446950
- 2. Beaulieu JM et al.. 2011. The physiology, signaling, and pharmacology of dopamine receptors.. Pharmacol Rev 63(1):182-217 PMID: 21303898
- 3. Missale C et al.. 1998. Dopamine receptors: from structure to function.. Physiol Rev 78(1):189-225 PMID: 9457173
- 4. Qing J et al.. 2022. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.. J Hepatol 76(2):394-406 PMID: 34648896
- 5. Yee AG et al.. 2025. Discrete spatiotemporal encoding of striatal dopamine transmission.. Science 389(6756):200-206 PMID: 40638729
- 6. Gurevich EV et al.. 2016. G protein-coupled receptor kinases as regulators of dopamine receptor functions.. Pharmacol Res 111:1-16 PMID: 27178731
- 7. Littlepage-Saunders M et al.. 2024. G protein-coupled receptor modulation of striatal dopamine transmission: Implications for psychoactive drug effects.. Br J Pharmacol 181(22):4399-4413 PMID: 37258878
- 8. Zhang F et al.. 2024. G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic targets.. Hypertens Res 47(9):2317-2336 PMID: 38961282
